SCHEMBL6492204

SCHEMBL6492204

CCCCCc1cn(-c2c(C(C)C)cccc2C(C)C)c(=O)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1

nearest known ligand 0.57

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
AGTR1 P30556 10/20 0.57
AGTR2 P50052 10/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6500257 0.98 AGTR1 (0.59) AGTR1AGTR2
SCHEMBL6500591 0.95 AGTR1 (0.52) AGTR1AGTR2
SCHEMBL6491965 0.95 AGTR1 (0.52) AGTR1AGTR2
SCHEMBL6502172 0.95 AGTR1 (0.52) AGTR1AGTR2
SCHEMBL6492185 0.95 AGTR1 (0.52) AGTR1AGTR2
SCHEMBL6503560 0.95 AGTR1 (0.52) AGTR1AGTR2
SCHEMBL6491215 0.95 AGTR1 (0.52) AGTR1AGTR2
SCHEMBL6501431 0.95 AGTR1 (0.52) AGTR1AGTR2
SCHEMBL6502461 0.94 AGTR1 (0.53) AGTR1AGTR2
SCHEMBL6492036 0.93 AGTR1 (0.51) AGTR1AGTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6858636-B2 1-phenyl imidazol-2-one biphenylmethyl compounds for treatment of circulatory disorders G.D. SEARLE & CO. (US) 2005-02-22 US disclosed
US-20040048911-A1 1-phenyl imidazol-2-one biphenylmethyl compounds for treatment of circulatory disorders G. D. SEARLE & CO. 2004-03-11 US disclosed
US-6630497-B2 1-phenyl imidazol-2-one biphenylmethyl compounds for treatment of circulatory disorders G.D. SEARLE & CO 2003-10-07 US disclosed
US-20020038035-A1 1-phenyl imidazol-2-one biphenylmethyl compounds for treatment of circulatory disorders G.D. SEARLE & CO. 2002-03-28 US disclosed
EP-0690854-B1 1-PHENYL-IMIDAZOL-2-ONE BIPHENYLMETHYL COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS SEARLE & CO (US) 2000-07-12 EP disclosed
EP-0978515-A2 1-(substituted phenyl)-4-biphenylmethyl-imidazol-2-one derivatives, their preparation and their use as angiotensin II antagonists G.D. SEARLE & CO. (US) 2000-02-09 EP disclosed
WO-1994021629-A1 1-PHENYL-IMIDAZOL-2-ONE BIPHENYLMETHYL COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS G.D. SEARLE & CO. (US) 1994-09-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020038035-A1 1-phenyl imidazol-2-one biphenylmethyl compounds for treatment of circulatory disorders AGTR1, AGTR2, REN AGTR1 1/4885AGTR2 2/4885
US-20040048911-A1 1-phenyl imidazol-2-one biphenylmethyl compounds for treatment of circulatory disorders AGTR1, AGTR2, REN AGTR1 1/4885AGTR2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.